| Assessment Status | Rapid Review Complete |
| HTA ID | 21019 |
| Drug | Olaparib |
| Brand | Lynparza® |
| Indication | As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. |
| Assessment Process | |
| Rapid review commissioned | 11/05/2021 |
| Rapid review completed | 15/06/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that olaparib not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
